How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations [Yahoo! Finance]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The average fair value estimate on Gossamer Bio has reset from about US$9.50 to roughly US$3.69, signaling a steep reassessment of what analysts think the shares may be worth. That shift lines up with Street research that now clusters price targets between US$0.30 and US$5, as views split between enthusiasm around seralutinib and concerns about regulation and the balance sheet. Read on to see how this evolving narrative is taking shape and what you might want to watch next. Stay updated as the Fair Value for Gossamer Bio shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Gossamer Bio. What Wall Street Has Been Saying ?? Bullish Takeaways Oppenheimer keeps an Outperform rating and a US$3 target, pointing to a key opinion leader view that seralutinib may have a high likelihood of approval in pulmonary arterial hypertension, given its inhaled PDGFR targeting and focus on vascular remodeling. Wedbush, despit
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSSGlobeNewswire
- Gossamer Bio (GOSS) had its "neutral" rating reaffirmed by Cantor Fitzgerald.MarketBeat
- Biotech company cuts half its staff after disappointing trial sees stock plummet [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSPR Newswire
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsGlobeNewswire
GOSS
Earnings
- 3/17/26 - Miss
GOSS
Sec Filings
- 3/24/26 - Form SCHEDULE
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- GOSS's page on the SEC website